Cargando…
Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish popul...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595898/ http://dx.doi.org/10.1093/eurpub/ckad160.365 |
_version_ | 1785124977195876352 |
---|---|
author | Emecen, A N Siyve, N Unal, B |
author_facet | Emecen, A N Siyve, N Unal, B |
author_sort | Emecen, A N |
collection | PubMed |
description | BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish population-specific model. METHODS: We analyzed data from Turkey's Chronic Diseases and Risk Factors study, which examined CVD incidence from 2011 until 2017. After excluding those with prior CVD history, a total of 7239 individuals aged 40 to 80 years were included in the analysis. The performance of Globorisk in predicting CVD was assessed using the C-index. With demographic, dietary, anthropometric and Globorisk variables; we used backward stepwise logistic regression to select the final model (Turkish CVD-TCVD). Lastly, the TCVD model was internally validated and calibrated with 200 bootstrap replicates. RESULTS: Out of 7239 participants (mean age: 53.9±10.3), women: 52.3%); 766 developed CVD within six years (cumulative incidence rate: 10.6%). The C-index of the Globorisk was 0.72 with sensitivity and specificity being 68.2% and 67.3%. In the final TCVD model, backward stepwise selection identified age (odds ratio-OR: 1.06, 95% Cl: 1.05-1.07), diabetes (OR:1.83, 1.47-2.28), body mass index (OR:1.02, 1.01-1.04), high waist-hip ratio (OR:1.37, 1.13-1.66) and systolic blood pressure (OR:1.01, 1.00-1.01) as significant predictors for CVD. C-index was 0.73 with sensitivity and specificity being 72.9%, and 62.9%. Examination of the calibration plot showed signs of overprediction when the actual CVD probability was >20%. CONCLUSIONS: Laboratory-based Globorisk score had a good fit in the Turkish population. TCVD model had better sensitivity than Globorisk. Adding of waist-hip ratio to the Globorisk score could improve predictive CVD models in the Turkish population. KEY MESSAGES: • External validation of laboratory-based Globorisk showed good predictive accuracy in the Turkish population. • Although more challenging to measure, adding of waist-hip ratio to the laboratory-based Globorisk score could improve predictive cardiovascular disease models in the Turkish population. |
format | Online Article Text |
id | pubmed-10595898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105958982023-10-25 Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases Emecen, A N Siyve, N Unal, B Eur J Public Health Parallel Programme BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish population-specific model. METHODS: We analyzed data from Turkey's Chronic Diseases and Risk Factors study, which examined CVD incidence from 2011 until 2017. After excluding those with prior CVD history, a total of 7239 individuals aged 40 to 80 years were included in the analysis. The performance of Globorisk in predicting CVD was assessed using the C-index. With demographic, dietary, anthropometric and Globorisk variables; we used backward stepwise logistic regression to select the final model (Turkish CVD-TCVD). Lastly, the TCVD model was internally validated and calibrated with 200 bootstrap replicates. RESULTS: Out of 7239 participants (mean age: 53.9±10.3), women: 52.3%); 766 developed CVD within six years (cumulative incidence rate: 10.6%). The C-index of the Globorisk was 0.72 with sensitivity and specificity being 68.2% and 67.3%. In the final TCVD model, backward stepwise selection identified age (odds ratio-OR: 1.06, 95% Cl: 1.05-1.07), diabetes (OR:1.83, 1.47-2.28), body mass index (OR:1.02, 1.01-1.04), high waist-hip ratio (OR:1.37, 1.13-1.66) and systolic blood pressure (OR:1.01, 1.00-1.01) as significant predictors for CVD. C-index was 0.73 with sensitivity and specificity being 72.9%, and 62.9%. Examination of the calibration plot showed signs of overprediction when the actual CVD probability was >20%. CONCLUSIONS: Laboratory-based Globorisk score had a good fit in the Turkish population. TCVD model had better sensitivity than Globorisk. Adding of waist-hip ratio to the Globorisk score could improve predictive CVD models in the Turkish population. KEY MESSAGES: • External validation of laboratory-based Globorisk showed good predictive accuracy in the Turkish population. • Although more challenging to measure, adding of waist-hip ratio to the laboratory-based Globorisk score could improve predictive cardiovascular disease models in the Turkish population. Oxford University Press 2023-10-24 /pmc/articles/PMC10595898/ http://dx.doi.org/10.1093/eurpub/ckad160.365 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Parallel Programme Emecen, A N Siyve, N Unal, B Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title | Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title_full | Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title_fullStr | Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title_full_unstemmed | Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title_short | Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases |
title_sort | validation of globorisk in turkish people and development of a new model for cardiovascular diseases |
topic | Parallel Programme |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595898/ http://dx.doi.org/10.1093/eurpub/ckad160.365 |
work_keys_str_mv | AT emecenan validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases AT siyven validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases AT unalb validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases |